Humane Genomics

Humane Genomics is a private, preclinical-stage biotech founded in 2018, headquartered in San Diego, CA, USA. The company leverages a proprietary synthetic virology platform to design and build cancer-killing RNA viruses with enhanced selectivity and potency. Its lead programs, focused on liver cancer and other solid tumors, are engineered for systemic delivery and are advancing towards clinical development, supported by key manufacturing and facility partnerships.

A synthetic virology platform for the computer-aided design, DNA synthesis, and rapid assembly of engineered oncolytic RNA viruses, primarily based on Vesicular Stomatitis Virus (VSV). The platform incorporates selective infection and replication mechanisms (e.g., aptazyme switches) for cancer cell-specific targeting.

Humane Genomics competes in the oncolytic virotherapy space against companies like Amgen (T-VEC), DNAtrix, and Turnstone Biologics, as well as numerous preclinical platforms. Its key differentiators are its synthetic biology-driven design for systemic delivery and a two-factor authentication safety mechanism aimed at superior selectivity.